After Cantor Fitzgerald and RBC Capital gave Dynavax (NASDAQ: DVAX) a Buy rating last month, the company received another Buy, this time from Cowen & Co. Analyst Phil Nadeau maintained a Buy rating on Dynavax yesterday and set a price target of $30. The company’s shares closed yesterday at $6.35, close to its 52-week low of $5.89.
According to TipRanks.com, Nadeau is a 4-star analyst with an average return of 6.1% and a 48.5% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical Inc., Phasebio Pharmaceuticals Inc, and Rocket Pharmaceuticals Inc.
Dynavax has an analyst consensus of Strong Buy, with a price target consensus of $25.67, which is a 304.3% upside from current levels. In a report issued on May 9, RBC Capital also maintained a Buy rating on the stock with a $19 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $17.05 and a one-year low of $5.89. Currently, Dynavax has an average volume of 1.18M.
Based on the recent corporate insider activity of 26 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the development and discovery of novel vaccines and immuno-oncology therapeutics. It focuses on leveraging the body’s innate and adaptive immune responses through toll-like receptor stimulation. It offers products for vaccines, cancer immunotherapy, and immune-mediated diseases.
